Alzheimer’s drug donanemab: what promising trial means for treatments

Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects. By Sara Reardon https://www.nature.com/articles/d41586-023-01537-5?utm_source=Live+Audience&utm_campaign=b86875fed9-nature-briefing-daily-20240507&utm_medium=email&utm_term=0_b27a691814-b86875fed9-50432164